Opiates, cocaine, and metabolites were quantified by liquid chromatography-mass spectrometry (LC-MS) in 284 urine specimens, collected thrice weekly, to monitor possible drug relapse in 15 pregnant heroin-dependent women. Opiates were detected in 149 urine specimens (52%) with limits of quantification (LOQ) of 10-50 µg/L. Morphine, morphine-3glucuronide, and/or morphine-6-glucuronide were positive in 121 specimens; 6-acetylmorphine, a biomarker of heroin ingestion, was quantifiable in only 7. No heroin, 6-acetylcodeine, papaverine, or noscapine were detected. One hundred and sixty-five urine specimens (58%) from all 15 participants were positive for one or more cocaine analytes (LOQ 10-100 µg/L). Ecgonine methylester (EME) and/or benzoylecgonine were the major cocaine biomarkers in 142. Anhydroecgonine methylester, a biomarker of smoked cocaine, was positive in six; cocaethylene and/or ecgonine ethylester, biomarkers of cocaine and ethanol co-ingestion, were found in 25. At the current Substance Abuse Mental Health Services Administration cutoffs for total morphine (2000 µg/L), codeine (2000 µg/L), 6-acetylmorphine (10 µg/L), and benzoylecgonine (100 µg/L), 16 opiate-and 29 cocaine-positive specimens were identified. Considering 100 µg/L EME as an additional urinary cocaine biomarker would identify 51 more positive cocaine specimens. Of interest is the differential pattern of opiate and cocaine biomarkers observed after LC-MS as compared to gas chromatography-mass spectrometry analysis.
Introduction
Illicit drug use is increasing worldwide with millions of individuals reporting cocaine, heroin, amphetamines, cannabis, and other drug use, all which substantially affect human health and behavior (1) . A wide variety of analytical methods and alternative matrices are available for monitoring illicit drug consumption (2, 3) . Urine drug testing is the "gold standard" for monitoring in drug treatment, criminal justice, and workplace drug-testing programs because it is an established, reliable, standardized, inexpensive, and widely available technology (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . Sampling urine is physically non-invasive and generally provides a large specimen volume. Urine is a simple, aqueous matrix containing high concentrations of drugs and metabolites as compared to other biofluids (14) . Urine testing provides a relatively long window of drug detection, from several days for opiates and cocaine to several weeks following chronic cannabinoid use (15, 16) . In general, urine is first screened to identify presumptive positive specimens followed by a more specific gas chromatography-mass spectrometry (GC-MS) or liquid chromatography (LC)-MS assay to confirm the presence of a limited number of analytes at pre-specified cutoff concentrations. LC-MS offers advantages over GC-MS for urine opiate and cocaine analyses including excellent selectivity achieved with specific precursor and product ions rather than the need to achieve chromatographic separation, direct injection of diluted urine minimizing specimen preparation, no derivatization, and improved detection of specific biomarkers of heroin exposure. The main disadvantage of LC-MS is the important requirement to minimize matrix effect and determine ion suppression or enhancement of analytes of interest. Inclusion of deuterated internal standards can minimize these effects but may not entirely compensate for matrix effects. Also, GC-MS instrumentation is less expensive, and personnel generally have more experience with this technique, although this is changing rapidly.
Heroin rapidly hydrolyzes to 6-acetylmorphine (6AM) and then to morphine, which is primarily conjugated with glucuronic acid (Figure 1 ) or sulfate to facilitate urinary excretion (17) . The glucuronide conjugate of morphine was reported to be sixfold more abundant than free morphine in human urine (18) . Presence of the heroin biomarker 6AM definitively identifies heroin exposure (19) (20) (21) .
Cocaine is a legitimate anesthetic for eye, ear, nose, and throat procedures, but it is more frequently abused for its euphoric effects by the intravenous, smoked, and insufflation routes. It is less toxic when taken orally because substantial hydrolysis occurs in the gastrointestinal tract. The primary metabolites of cocaine are benzoylecgonine (BE), ecgonine methylester (EME), and ecgonine ( Figure 2 ), all of which are inactive biomarkers. Norcocaine, an active metabolite, and ethylecgonine, hydroxycocaine, and methylecgonidine also are minor urinary biomarkers. When cocaine is ingested in combination with alcohol, cocaethylene also may be produced (22) .
Objectives of this research were characterization of the disposition of heroin, cocaine, and metabolites in urine of pregnant opiate-dependent women following drug relapse and comparison of drug detection rates with different drug biomarkers and at different cutoff concentrations. Cutoffs evaluated include the method limit of quantitation (LOQ), drug treatment cutoffs, and current and proposed cutoffs for workplace drug testing mandated by the Substance Abuse Mental Health Services Administration (SAMHSA, 1994) (23), (SAMHSA, 1998) (24) . In addition, the value of EME as a urinary cocaine biomarker is explored.
Methods

Human participants
In a study conducted at the Center for Addiction and Pregnancy (CAP), Johns Hopkins Bayview Medical Center (JHBMC, Baltimore, MD), 15 pregnant opiate-dependent women were provided comprehensive treatment including prenatal care, psychological counseling, methadone maintenance, child care, and transportation (25) (26) (27) . The study was approved by the JHBMC and National Institute on Drug Abuse Institutional Review Boards and participants provided written informed consent. All women met DSM-IV diagnostic criteria for current opiate dependence; some also met criteria for current cocaine dependence. They resided for at least one week at CAP for initiation of methadone treatment. Throughout gestation, participants received daily methadone (mean ± SD) 75 ± 17 mg/day (range 45-110 mg/day), weekly individual and group counseling, vouchers for negative urine drug tests as part of behavioral contingency management, and specialized prenatal care.
Urine collection and on-site analysis
Urine drug testing was performed three times per week as a deterrent to illicit drug use; drug testing was an integral component of the contingency management program that rewarded drug abstinence (28) . Patients participated in the study throughout gestation and visited the clinic seven days per week to receive methadone. Urine specimens were collected under direct observation by trained staff and stored at -20°C until analysis. The number of specimens collected was dependent upon the length of study enrollment. Urine specimens were initially screened on-site for the presence or absence of opiates and cocaine by On-Trak technology (29) . Immediate results were available to determine eligibility for voucher incentive interventions. Urine specimens were later reanalyzed by LC-MS.
Specimen analysis
Simultaneous quantification of unconjugated opiates (heroin, morphine, normorphine, 6AM, codeine, 6-acetylcodeine, norcodeine, noscapine, papaverine), and cocaine biomarkers [cocaine, ecgonine, EME, ecgonine ethylester (EEE), anhydroecgonine methylester (AEME), p-hydroxybenzoylecgonine (p-OHBE), m-hydroxybenzoylecgonine (m-OHBE), BE, benzoylnorecgonine (BNE), p-hydroxycocaine, m-hydroxycocaine, norcocaine, cocaethylene, and norcocaethylene] were achieved with atmospheric pressure chemical ionization LC-MS according to a previously published method (12) . Identification and quantification was based upon selected reaction monitoring (SRM) employing the precursor and product ions presented in Tables I and II . Deuterated internal standards were included whenever commercially available. Briefly, 100 µL urine was fortified with 10 µL of mixed internal standard working solution. Specimens were briefly vortex mixed and centrifuged to remove large particles (5 min at 510 × g). Ten microliters supernatant was directly injected onto the LC-MS. LOQs for opiates are reported in Table I , and cocaine biomarkers in Table II . Evaluation of matrix effects showed low bias (82.5-109.2% efficiency) and imprecision (< 16%).
Glucuronidated analytes [morphine-3-glucuronide (M3G), morphine-6-glucuronide (M6G), and codeine-6-glucuronide (C6G)] were analyzed in a separate urine aliquot by electrospray LC-MS according to a previously published procedure (30) . Identification and quantification was based on SRM using the precursor and product ions presented in Table I . Imprecision and analytical recovery of the method were evaluated at three concentrations (70, 350, and 3500 µg/L) over the linear dynamic range of 25-4000 µg/L. Method imprecision was ≤ 12%, and analytical recovery ranged from 93 to 106% for all analytes. No significant matrix effect was observed.
All LC-MS experiments were performed with the LCQ DECA XP or XP Plus ion trap MS interfaced to a Surveyor HPLC system (ThermoFinnigan, San Jose, CA). Data were acquired and analyzed using Xcalibur™ software version 1.2. Analyte concentrations exceeding the upper LOQ of the validated method were reanalyzed after adequate dilution with blank urine. The integrity of dilution was documented during method validation.
Evaluation of detection rates at different opiate and cocaine cutoffs
Urine specimens were considered positive if any of several biomarkers was present at a concentration equal to or higher than LOQs of the method. LOQs for opiate and cocaine biomarkers are included in Tables I and II , respectively. Additional cutoffs include 300 µg/L for total morphine and total codeine, cutoffs frequently employed in drug treatment pro-grams, and formerly mandated for workplace drug testing by SAMHSA. The opiate cutoff for these analytes was raised by SAMHSA to 2000 µg/L as most positive opiate tests were not acted upon because of intake of legitimate medication or opioid-containing foodstuffs (24) . 6AM, a definitive heroin biomarker, was confirmed at 10 µg/L. BE concentrations ≥ 150 (23) and 100 µg/L (24) were also evaluated to compare previous and proposed SAMHSA cutoff concentrations, scheduled for introduction in May 2010 (31) . In addition, due to the prevalence of EME in urine after cocaine ingestion, detection rates were evaluated with the addition of EME as well as BE.
Results
Clinical specimens
Subjects (11 African Americans and 4 Caucasians) enrolled in the study between 8 and 28 weeks of gestation, were firsttime drug treatment seekers, and were 29.5 ± 6.7 years of age (range . Mean number of weeks in the study was 17.0 ± 5.8 with a range of 8.2-27.2 weeks. A total of 284 urine specimens were collected with a mean volume of 60 ± 12 mL, ranging from 8 to 140 mL, and a mean urine pH of 6.7 ± 0.8 (range 4.3-8.8).
Heroin and metabolites in urine
Simultaneous analysis of heroin and metabolites in the urine of pregnant substance abuse treatment patients revealed 52% opiate-positive specimens. A detailed listing of the prevalence of opiate analytes, median, mean, and range of concentrations are shown in Table I . Of 15 subjects, only one had no opiatepositive results, five subjects had < 20% positive specimens, eight subjects 20% to 90%, and in one subject, more than 90% of urine specimens were positive. Opiate and metabolite (M3G, M6G, and normorphine) distribution in all opiate-positive specimens is depicted in Figure  3 . M3G and/or M6G, products of phase II metabolism of morphine, were identified in the greatest number: 119 of 284 urine specimens (42%). More opiate-positive specimens contained M3G (92) than M6G (65) except in specimens from one subject (subject G), which had quantifiable M6G in almost all urine collections. Eleven subjects had urine specimens positive for both M3G and M6G. In eight of these, M3G concentrations always were greater than M6G (Table III) . Table III shows the median and range of M6G/M3G ratios in all specimens containing both analytes.
Total morphine (free morphine, M3G, and M6G) concentrations were always greater than total codeine (free codeine and C6G) concentrations in the 21 specimens containing both, which suggests that licit codeine medication was not the source of opiate-positive urine specimens. Surprisingly, normorphine, an analyte rarely monitored, was detected in the next highest number of specimens (42) . If free morphine was employed to identify opiate exposure, many positive specimens would be missed as only 12 of 119 contained this analyte. 6AM, a specific biomarker for heroin use, was present in only seven specimens; and heroin and acetylcodeine, alternative heroin biomarkers, were not detected in any specimen. Two other alkaloids, papaverine and noscapine, were not detected either.
Urinary opiate excretion in one representative participant (Subject B) throughout the study is illustrated in Figure 4 . In this subject, M3G, M6G, and free morphine were identified with M3G concentrations always exceeding those of M6G. No consistent ratio or statistically significant relationship among analytes was identified.
Cocaine and metabolites in urine
Simultaneous analysis of cocaine and metabolites in urine specimens from pregnant substance abuse treatment patients yielded 58% cocaine-positive specimens (Table II) . All 15 participants tested positive for cocaine or its metabolites at some point during treatment. Seven subjects had between 20 and 50% cocaine-positive specimens, five between 50 and 80%, and three more than 80% positive. All of one subject's specimens were cocaine or metabolites positive, often with high analyte concentrations.
Cocaine and metabolite (BE, EME, and BNE) distribution in cocaine-positive specimens is depicted in Figure 5 . BE is the analyte most often monitored in treatment, workplace, and postmortem settings, although EME prevalence (43.3%) was higher than for BE (29.7%). Furthermore, the LOQ concentration for EME (50 µg/L) was fivefold higher than BE (10 µg/L). At the LC-MS LOQ, EME and BE were identified concurrently in 24.6% of cocaine-positive specimens; 17.6% tested positive for EME only and 4.6% for BE only. Ecgonine, a degradation product of BE, was identified in 30 specimens. Fewer specimens (n = 6) were positive for AEME with an LOQ of 100 µg/L. Nineteen specimens were positive for m-and p-OHBE, with higher median p-OHBE concentrations. More specimens (n = 25) were positive for EEE than CE (1). p-OHCOC and norcocaethylene were not detected. EME, BE, and BNE was the most prevalent analyte combination. Cocaine analyte concentrations in urine specimens across the course of the study are illustrated for one representative subject Subject C in Figure 6 . High concentrations of cocaine metabolites in numerous urine specimens suggested consistent cocaine relapse throughout pregnancy. Concentrations of EME and BE varied over time, but EME concentrations were always higher.
Opiate and cocaine detection rates in urine at different cutoff concentrations
One hundred and forty-nine positive urine specimens (52.5%) contained more than 10 µg/L total morphine, total codeine, and/or 6AM. Only 35 were positive at the former SAMHSA 1994 cutoff for total morphine and/or codeine of 300 µg/L. This is the same cutoff concentration typically applied in drug treatment. Of these, only about one-fourth of specimens (n = 9) were positive at the revised SAMHSA cutoff of 2000 µg/L for total morphine or codeine. Seven specimens were positive for 6AM at the 10 µg/L cutoff. Free morphine (n = 112) and free codeine (n = 15) were prevalent at the LC-MS LOQ. BE was detected above the method LOQ (10 µg/L) in 84 cocaine-positive specimens, but only 29 (18%) were positive at the proposed 100 µg/L detection limit and 26 specimens (16%) at the 150 µg/L detection limit. Seventeen specimens were positive for cocaine with the treatment cutoff concentration of 300 µg/L BE. The LC-MS method at the lower LOQ identified 55 BE-positive specimens compared to the revised SAMHSA cutoff. Addition of EME as a biomarker would increase cocainepositive specimens by 51 at the LC-MS LOQ and by 13 at 100 µg/L compared to the previous SAMHSA cutoff of 150 µg/L.
Discussion
Urine drug testing is an integral component of drug treatment, criminal justice, and workplace programs. Drug metabolites tend to exceed parent drug concentrations in urine. Quantitative analysis of drugs in urine is traditionally performed by GC-MS. Although, this technique is well-established, sensitive, and specific, GC-MS analysis usually requires tedious and time-consuming specimen preparation (32) . In particular, specimen clean-up and concentration by SPE, and subsequent derivatization of non-volatile analytes are labor-intensive processes. On the other hand, 70% of routine toxicological samples can be analyzed by LC (33) . LC combined with spectrophotometric detection lacks specificity and sensitivity and also requires extensive specimen cleanup (34) . LC-MS offers high sensitivity and specificity and frequently permits simultaneous analysis of a wide polarity range for multiple drug classes (11, 12, 35, 36) .
The major opiate analytes detected by the present LC-MS method were M3G, M6G, normorphine, and morphine with minor metabolites detected only in highly opiate-positive urine specimens. Morphine glucuronide concentrations (maximum 3546 µg/L) exceeded those of free morphine (maximum 3359 µg/L). Participants typically had more M3Gthan M6G-positive specimens, although one subject had almost 100% M6G-positive specimens. According to Antonilli et al. (18) , if the ratio of M6G/M3G is > 1, intravenous heroin is suggested while a ratio < 1 indicates oral heroin. Of 15 participants in our study, only subject G (Table III) had a ratio of M6G/M3G > 1. Based on self-reported route of heroin administration and our interpretation of the opiate disposition in these specimens, the primary route in our population is intravenous heroin, contradicting the Antonilli proposal (18) . Also, total morphine to total codeine ratios were calculated to aid our interpretation of the ingested opiate. Total morphine to total codeine ratios were always greater than 1, (2.2-101.5), which suggests heroin or morphine exposure not codeine. This is in accordance with Al-Asmari et al. (37) , who reported seven postmortem cases following intravenous heroin use; total morphine to total codeine ratios were 12-70. M6G/M3G ratios for the postmortem cases were less than 1 (ranged from 0.03 to 0.1), which also contradicts Antonilli's hypothesis (18) .
Another important aspect to quantifying opiates by LC-MS is the direct analysis of M3G and M6G without the need for enzyme/chemical hydrolysis, which is a time-consuming and expensive process. More than 97 opiate-positive specimens were identified solely by the presence of M3G and M6G.
6AM in urine clearly documents recent heroin exposure. 6AM was detected in only seven urine specimens from one participant, confirming heroin use. Free and total morphine concentrations in this participant were higher than those of free and total codeine. Other participants had no 6AM, but total morphine concentrations were much higher than those of total codeine. Interpretation of this type of opiate pattern in urine is more difficult as morphine or even morphine containing foodstuffs could be the source of opiates. This demonstrates one of the major weaknesses of urine drug testing to identify heroin use. 6AM has a short detection window in urine and is frequently not detectable.
The presence of cocaine, its metabolites, pyrolysis products, and/or ethanol adducts in biological fluids provide markers of cocaine use and its possible route of administration (38, 39) . The catabolism of cocaine results primarily in the ester hydrolysis products BE and, to a lesser extent, EME (40) . In vivo, BE is predominantly produced from chemical hydrolysis of cocaine, whereas EME results from enzymatic hydrolysis (41) . Although neither is psychoactive, these biomarkers are highly effective in detecting cocaine exposure because of their long half-lives in urine. According to Lewis and coworkers, BE concentration in urine was 2-3-fold higher than EME in five postmortem cases analyzed for cocaine and metabolites by GC-MS (42) . Cardona et al. (43) also confirmed the presence of BE in higher concentrations than EME. In our study, BE also was in higher concentrations than EME but at a lower prevalence, despite the higher LOQ for EME. In a study of the instability of cocaine in contaminated urine for 30 days at 25°C, cocaine was completely degraded, primarily to EME and to a lesser extent BE (44) . Further support for higher urinary EME than BE comes from Isenschmid et al. (45) , who reported that enzymatic hydrolysis of cocaine to EME exceeds production of BE.
When cocaine is smoked, a biomarker product, AEME, is produced. AEME and its metabolite, anhydroecgonine (AE), are indicators of crack smoking (46) . AEME was identified in six positive urine specimens (2.1%) of three subjects, which suggests the smoked route of administration. However, AEME has a short window of drug detection in urine and appears to underestimate the amount of crack cocaine use; most participants reported cocaine smoking as the primary route of drug administration. Presence of AEME should be interpreted with caution following GC-MS analysis as possible conversion of cocaine to AEME at high injection port temperatures may occur (47, 48) . Lewis et al. (42) reported a mean conversion rate of 0.8% for cocaine to AEME following thermal decomposition. Another route of artifactual AEME formation was dehydration of EME in the heated injector port (49) . With the described disadvantages of GC-MS in quantifying cocaine and metabolites, LC-MS provides an alternative technique without artifact formation.
The concurrent use of cocaine and ethanol results in a biologically active molecule, CE, and two non-active metabolites, NCE and EEE. Cocaine and ethanol are frequently taken together with CE having a much longer lasting high (50) . CE is even more toxic than cocaine, and its potency results in an increased risk of death from overdose (51) . CE was detected only in one specimen, but its metabolite, EEE, was detected in 12. Concentrations of cocaine metabolites (BE, BNE, EME, and EEE) excreted in urine followed the same pattern as described by Paul et al. (52) .
Another important aspect of this study is comparison of results at the low detection limits of the LC-MS method and at the proposed SAMHSA cutoffs. Application of the 1998 revised SAMHSA-recommended detection concentrations for confirmatory urine analysis identified far fewer positive specimens than the LC-MS method limit. Only 7% of opiate and 10% of cocaine-positive specimens were detected with the limits proposed by SAMHSA, and the LC-MS method identified 52% and 30% opiate-and cocaine-positive specimens, respectively. Clearly, the window of drug detection was expanded with the lower detection concentration limits. Another important issue was detection of EME but not BE in 50 specimens with the 50 µg/L LC-MS cutoff compared to 13 at the revised SAMHSA cutoff of 100 µg/L (Table IV) . Presently, SAMHSA only includes BE as a biomarker for detection of cocaine use. Adding EME as an additional marker would increase the number of cocainepositive urine specimens at the revised SAMHSA 1998 cutoff of 100 µg/L to 42 specimens (14.8%) or 29 specimens (10.2%) if the 150 µg/L was applied. However, a limitation could be that a single opiate or cocaine ingestion may have produced additional positive results at the LOQ of the method, reflecting residual drug excretion rather than new episodes of drug use.
Conclusions
LC-MS successfully achieved simultaneous quantification of opiate and cocaine and their metabolites, including glucuronic acid conjugates with high sensitivity and selectivity and a shorter processing time. Direct analysis of morphine conjugates increased the number of opiate-positive specimens compared to the analysis of only free morphine. Including EME in confirmatory urine analysis may increase the total cocainepositive specimens.
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